secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001193125-24-251268
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago
--------------------------------------------------------------------

- Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
- GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.
- Installed base expanded to 2,821 units, adding 164 units in Q3.
- Repurchased $12.1M of stock during Q3; cash and securities $277.8M.
- FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/0001193125-24-251268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/d825275d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-251268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer